Dr BEN ABDELGHANI Meher

Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study.

M'Baloula J, Tougeron D, Boilève A, Jeanbert E, Guimbaud R, Ben Abdelghani M, Durand A, Turpin A, Quesada S, Blanc JF, Artru P, Toullec C, Trouilloud I, Pellat A, Touchefeu Y, Pinot J, Caroli-Bosc FX, Taïeb J, Doat S, Bouché O, Védie AL, de Mestier L, Muller M

Eur J Cancer. 2024 10 1;212:115051

Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients.

Assaf I, Bregni G, Anthoine G, Aparicio T, Artru P, Abdelghani MB, Buyse M, Chibaudel B, Coart E, Diaz M, Evrard C, Geboes K, Ghiringhelli F, Puleo F, Raimbourg J, Vandamme T, Van den Eynde M, Hendlisz A, Sclafani F

Clin Colorectal Cancer. 2024 09 3;:

Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trial.

Adenis A, Da Silva A, Ben Abdelghani M, Bourgeois V, Bogart E, Turpin A, Evin A, Proux A, Galais MP, Jaraudias C, Quintin J, Bouquet G, Samalin E, Bremaud N, Javed S, Henry A, Kurtz JE, Cornuault-Foubert D, Vandamme H, Lucchi E, Pannier D, Belletier C, Paul M, Touzet L, Penel N, Chvetzoff G, Le Deley MC

EClinicalMedicine. 2024 08;74:102470

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.

Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet JB, Harlé A, Rebours V, Turpin A, Abdelghani MB, Mitry E, Biagi J, Chanez B, Bigonnet M, Lopez A, Evesque L, Lecomte T, Assenat E, Bouché O, Renouf D, Lambert A, Monard L, Mauduit M, Cros J, Iovanna J, Dusetti N

Ann Oncol. 2024 06 19;:

Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.

Botsen D, Chabaud S, Perrier H, Ammarguellat H, Jestin-Le-Tallec V, Olesinski J, Toullec C, Aparicio T, Ben Abdelghani M, Borg C, Bouche O, Coutzac C, Devaud H, Di Fiore F, Dubreuil O, Evesque L, Huguenin B, Muller M, Poureau PG, Oularue E, Tougeron D, Zaanan A, Ammari S, De Sousa Carvalho N, Decazes P, De La Fouchardiere C

Dig Liver Dis. 2024 05 17;:

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C

Lancet Oncol. 2024 04;25(4):518-528

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.

Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, Vernerey D, Taieb J, Guimbaud R, Tougeron D

Eur J Cancer. 2024 03 21;202:114033

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.

Parisi A, Delaunay B, Pinterpe G, Hollebecque A, Blanc JF, Bouattour M, Assenat E, Ben Abdelghani M, Sarabi M, Niger M, Vivaldi C, Mandalà M, Palloni A, Bensi M, Garattini SK, Tougeron D, Combe P, Salati M, Rimini M, Cella CA, Tucci M, Diana A, Mori E, Longarini R, Artru P, Roth G, Evesque L, Vienne A, Turpin A, Hiret S, Bourgeois V, Herve C, Paulon R, Stacoffe M, Malka D, Neuzillet C, Edeline J, Lievre A, Guimbaud R, Chapda MCP, Rimassa L, Giampieri R, Valle J, Berardi R, Fares N

Eur J Cancer. 2024 02 6;200:113587

Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.

Flecchia C, Auclin E, Alouani E, Mercier M, Hollebecque A, Turpin A, Mazard T, Pernot S, Dutherage M, Cohen R, Borg C, Hautefeuille V, Sclafani F, Ben-Abdelghani M, Aparicio T, De La Fouchardière C, Herve C, Perkins G, Heinrich K, Kunzmann V, Gallois C, Guimbaud R, Tougeron D, Taieb J

Br J Cancer. 2023 12 15;:

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.

Nicolle R, Bachet JB, Harlé A, Iovanna J, Hammel P, Rebours V, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lopez A, Biagi J, François E, Artru P, Lambert A, Renouf DJ, Monard L, Mauduit M, Dusetti N, Conroy T, Cros J

J Clin Oncol. 2023 11 14;:JCO2202668

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Boige V, Blons H, François E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, Mineur L, Galais MP, Villing AL, Hautefeuille V, Miglianico L, De La Fouchardière C, Genet D, Levasseur N, Levaché CB, Penel N, Mitry E, Jacquot S, Aparicio T, Brument E, Gourgou S, Castan F, Bouché O

JAMA Netw Open. 2023 09 5;6(9):e2333533

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.

Vendrely V, Ronchin P, Minsat M, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Darut-Jouve A, de la Fouchardière C, Giraud N, Breysacher G, Argo-Leignel D, Thimonnier E, Magné N, Ben Abdelghani M, Lepage C, Aparicio T,

Radiother Oncol. 2023 06 12;:109742

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

Gronnier C, Mariette C, Lepage C, Monterymard C, Jary M, Ferru A, Baconnier M, Adhoute X, Tavan D, Perrier H, Guerin-Meyer V, Lecaille C, Bonichon-Lamichhane N, Pillon D, Cojocarasu O, Egreteau J, D'journo XB, Dahan L, Locher C, Texereau P, Collet D, Michel P, Ben Abdelghani M, Guimbaud R, Muller M, Bouché O, Piessen G

Cancers (Basel). 2023 04 6;15(7):

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.

Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanan A

Gastric Cancer. 2023 03 7;:

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P,

JAMA Oncol. 2022 09 1;:

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.

Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, Dubreuil O, Evesque L, Ghiringhelli F, Kim S, Lesourd S, Neuzillet C, Phelip JM, Piessen G, Rochigneux P, Samalin E, Soularue E, Touchefeu Y, Tougeron D, Zaanan A, de la Fouchardière C

Dig Liver Dis. 2022 07 27;:

Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.

Edeline J, Hirano S, Bertaut A, Konishi M, Benabdelghani M, Uesaka K, Watelet J, Ohtsuka M, Hammel P, Kaneoka Y, Joly JP, Yamamoto M, Monard L, Ambo Y, Louvet C, Ando M, Malka D, Nagino M, Phelip JM, Ebata T

Eur J Cancer. 2022 Feb 16;164:80-87

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort.

Allart M, Leroy F, Kim S, Sefrioui D, Nayeri M, Zaanan A, Rousseau B, Ben Abdelghani M, de la Fouchardière C, Cacheux W, Legros R, Louafi S, Tougeron D, Bouché O, Fares N, Roquin G, Bignon AL, Maillet M, Pozet A, Hautefeuille V,

Dig Liver Dis. 2021 Aug 9;:

Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.

Caron B, Reimund JM, Ben Abdelghani M, Sondag D, Noirclerc M, Duclos B, Kurtz JE, Nguimpi-Tambou M

Pancreas. 2021 Aug 3;:

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.

Blanc JF, Khemissa F, Bronowicki JP, Monterymard C, Perarnau JM, Bourgeois V, Obled S, Abdelghani MB, Mabile-Archambeaud I, Faroux R, Seitz JF, Locher C, Senellart H, Villing AL, Audemar F, Costentin C, Deplanque G, Manfredi S, Edeline J,

Hepatol Int. 2021 Jan 9;:

MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.

Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V

Cancers (Basel). 2021 Jan 7;13(2):

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X

PLoS One. 2021 ;16(9):e0248222

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.

Boilève A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanié H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, Vernerey D, Turpin A, Neuzillet C

Eur J Cancer. 2020 Dec 3;143:55-63

Giraud N, Aparicio T, Ronchin P, Bazire LA, Le Malicot K, Lemanski C, Mirabel X, Étienne PL, Lièvre A, Cacheux W, Darut-Jouve A, de la Fouchardière C, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Saut O, Vendrely V

Cancer Radiother. 2020 Oct;24(6-7):772-773

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.

Aparicio T, Darut-Jouve A, Khemissa Akouz F, Montérymard C, Artru P, Cany L, Romano O, Valenza B, Le Foll C, Delbaldo C, Falandry C, Norguet Monnereau E, Ben Abdelghani M, Smith D, Rinaldi Y, Père Verge D, Baize N, Maillard E, Dohan A, Des Guetz G, Pamoukdjian F, Lepage C

J Geriatr Oncol. 2020 Apr 22;:

Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.

Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousinière A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF

Front Oncol. 2020 ;10:1304

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.

Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Des Guetz G

World J. Gastroenterol.. 2019 Aug 7;25(29):4007-4018

Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 - UCGI 35 - REGIRI).

Samalin E, Turpin A, Khemissa F, Zaanan A, Benabdelghani M, Senellart H, Gilabert M, Evesque L, Dahan L, Sefrioui D, Bouché O, De la Fouchardière C, Hennequin A, Monard L, Gourgou S, Lopez A

Ann. Oncol.. 2019 Jul;30 Suppl 4:iv21

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparico T, Hoeffel C,

Gut. 2019 May 17;:

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T

Clin Colorectal Cancer. 2019 May 3;:

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

Adenis A, Bennouna J, Etienne PL, Bogart E, Francois E, Galais MP, Ben Abdelghani M, Michel P, Metges JP, Dahan L, Conroy T, Ghiringhelli F, Drouillard A, El Hajbi F, Samalin E, Hiret S, Delaine-Clisant S, Mariette C, Penel N, Piessen G, Le Deley MC

Eur. J. Cancer. 2019 Feb 21;111:12-20

Cardiac Metastases of Small-Bowel Carcinoid.

El Ghannudi S, Ben Abdelghani M, Germain P, Blondet C, Romain B, Imperiale A

Circ Cardiovasc Imaging. 2019 Feb;12(2):e008405

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM

J. Clin. Oncol.. 2019 Feb 1;:JCO1800050

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB,

N. Engl. J. Med.. 2018 Dec 20;379(25):2395-2406

Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort.

Allart-Sava M, Le Roy F, Kim S, Sefrioui D, Mariette C, Zaanan A, Rousseau BJ, Ben Abdelghani M, De La Fouchardière C, Cacheux W, Legros R, Louafi S, Tougeron D, Fares N, Roquin G, Bignon Bretagne AL, Maillet M, Tchoundjeu B, Pozet A, Hautefeuille V

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii186

Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD.

Aparicio T, Darut Jouve A, Khemissa F, Montérymard C, Artru P, Cany L, Romano O, Valenza B, Le Foll C, Delbaldo C, Falandry C, Duluc M, Rinaldi Y, Legoux JL, Ben Abdelghani M, Assenat E, Dhooge M, Smith D, Des Guetz G, Lepage C

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii156

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

Aparicio T, Bouché O, Francois E, Retornaz F, Barbier E, Taieb J, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Bedenne L, Paillaud E,

Eur. J. Cancer. 2018 May 16;97:16-24

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.

Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A

Oncotarget. 2017 Nov 24;8(60):101383-101393

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C

BMC Cancer. 2017 Aug;17(1):574

First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.

Kotecki N, Hiret S, Etienne PL, Penel N, Tresch E, François E, Galais MP, Ben Abdelghani M, Michel P, Dahan L, Ghiringelli F, Bedenne L, Samalin E, Piessen G, Bennouna J, Peugniez C, El Hajbi F, Clisant S, Kramar A, Mariette C, Adenis A

Oncology. 2016 ;90(2):88-96

Zarzio, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.

Nahon S, Rastkhah M, Ben Abdelghani M, Soumoudronga RF, Gasnereau I, Labourey JL

Support Care Cancer. 2015 Oct 27.

Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.

Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Dufour P, Kurtz JE, Noel G

Dis Esophagus. 2014 Aug;27(6):560-7

Age impacts the pattern of care for elderly patients with rectal cancer.

Guillerme F, Clavier JB, Nehme-Schuster H, Leroy V, Heitz D, Schumacher C, Abdelghani MB, Brigand C, Kurtz JE, Noel G

Int J Colorectal Dis. 2014 Feb;29(2):157-63

[Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study].

Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Salze P, Noel G

Cancer Radiother. 2013 Jun;17(3):221-8

Cobalamin deficiency due to non-immune atrophic gastritis in elderly patients. A report of 25 cases.

Henoun Loukili N, Noel E, Ben Abdelghani M, Locatelli F, Blickle JF, Andres E

J Nutr Health Aging. 2005 Nov-Dec;9(6):462.

[A urachus cyst revealing a torpid Crohn's disease in a young adult with chronic fever].

Weitten T, Coca C, Ben Abdelghani M, Rohr S, Boujan E, Blickle JF, Andres E

Presse Med. 2005 Apr 23;34(8):581-2.